Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

About this update from Immuneering Corporation

[{"type":"image","alt":"Immuneering Corporation","displaySize":"","headline":null,"caption":"Immuneering Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fGFUZ0nWiGak7K0u9vVc2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313","width":300,"height":74}},"lazy":false},{"type":"text","content":"Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients","length":125,"tagName":"p"},{"type":"text","content":"Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025","length":131,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer. In this role, he will direct Immuneering’s clinical activities, providing medical and operational leadership for the company’s development programs including an ongoing Phase 2a study of lead program IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, and plans to initiate a pivotal Phase 3 clinical trial in pancreatic cancer.","length":651,"tagName":"p"},{"type":"text","content":"“The Phase 2a data we shared in January demonstrates the potential of IMM-1-104 to provide first line pancreatic cancer patients with a new option that is more effective and better tolerated than standard of care. Dr. Matushansky has dedicated his career to oncology – both as a researcher and as practicing oncologist working with cancer patients – and as a result, has a direct understanding of the patient experience,” said Ben Zeskind, Ph.D., CEO of Immuneering. “This is the perfect time to bring on a world-class CMO as we continue to execute our Phase 2a study and plan our pivotal study for IMM-1-104.”","length":610,"tagName":"p"},{"type":"text","content":"“In my clinical practice, I have seen firsthand how vitally important quality of life is to c...

More updates from Immuneering Corporation